In a twist, Amylyx's ALS drug will get a second crack at adcomm endorsement after FDA decides to reconvene experts - Endpoints News

After a close negative vote earlier this year, Amylyx Pharmaceuticals will get another attempt to persuade FDA advisors that its experimental ALS drug is effective. US regulators will hold a second meeting of the Peripheral and Central Nervous System Drugs Ad…

The bottom line story for the pharma industry coming out of the Cannes Lions show was fewer entries and fewer awards. And not only for Big Pharma brands, but across submissions and wins in the two ca… [+489 chars]

full article...